Skip to main content

Ebola Hemorrhagic Fever

2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sarepta Therapeutics
1 program
1
AVI-7537Phase 1
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
VRC-EBOADV018-00-VPPhase 11 trial
Active Trials
NCT00374309Completed48Est. May 2009
United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
AVI-7537PHASE_11 trial
Active Trials
NCT01593072Withdrawn0Est. Jan 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
United TherapeuticsAVI-7537
Allergy TherapeuticsVRC-EBOADV018-00-VP

Clinical Trials (2)

Total enrollment: 48 patients across 2 trials

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers

Start: Aug 2012Est. completion: Jan 20130
Phase 1Withdrawn

Experimental Vaccine for Prevention of Ebola Virus Infection

Start: Sep 2006Est. completion: May 200948 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.